thymoquinone has been researched along with alpha-synuclein in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhebshi, AH; Gotoh, M; Odawara, A; Suzuki, I | 1 |
| Ohnuma, K | 1 |
| Ardah, MT; Haque, ME; Merghani, MM | 1 |
3 other study(ies) available for thymoquinone and alpha-synuclein
| Article | Year |
|---|---|
Thymoquinone protects cultured hippocampal and human induced pluripotent stem cells-derived neurons against α-synuclein-induced synapse damage.
Topics: Action Potentials; alpha-Synuclein; Animals; Benzoquinones; Cells, Cultured; Hippocampus; Humans; Induced Pluripotent Stem Cells; Mutation; Neurons; Neuroprotective Agents; Primary Cell Culture; Rats, Wistar; Synapses; Synaptic Vesicles; Synaptophysin | 2014 |
Assays of traditional drugs using human neurons derived from pluripotent stem cells.
Topics: alpha-Synuclein; Animals; Benzoquinones; Hippocampus; Humans; Induced Pluripotent Stem Cells; Neurons; Neuroprotective Agents; Synapses | 2014 |
Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates α-synuclein aggregation in vitro.
Topics: alpha-Synuclein; Animals; Benzoquinones; Cell Line, Tumor; Corpus Striatum; Humans; Male; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Parkinsonian Disorders; Protein Aggregates | 2019 |